CRISPR Therapeutics (NASDAQ: CRSP) stock climbed 7% after receiving an upgrade from Evercore ISI, shifting from an In Line ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by equities researchers at Truist Financial from $100.00 to $120.00 in a report issued on Wednesday,Benzinga reports.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham ...

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Stifel analysts adjusted their outlook on CRISPR Therapeutics (NASDAQ:CRSP), currently trading at $43.09 with a market capitalization of $3.7 billion, reducing the price target to $49 from the ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49 ... and the technology-centric Nasdaq increased by 1.35%. Prior to today's trading, shares of the company had lost ...

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...